本指南旨在提供有关生殖器尖锐湿疣的全面信息,包括流行病学,临床特征,诊断和管理。指南提供了基于证据的诊断建议,亚洲成人生殖器尖锐湿疣的预防和治疗,包括合并感染艾滋病毒的患者。
方法:进行了PubMed搜索,使用关键词“尖锐湿疣”,“肛门疣”,“肛门生殖器疣”,“生殖器疣”和“生殖器HPV”。在过去的六年中,出版物共发现了3031个结果。对标题和摘要进行了仔细的审查,以找到所有与流行病学有关的研究,临床特征,诊断,尖锐湿疣的治疗和预防。
方法:描述的各种诊断程序是:1.PCR(LE:2b)。2.血清学(LE:2b)。3.原位杂交(LE:3)。
结论:1.疫苗接种(LE:1a):四价疫苗降低了接种和未接种的接触者中肛门生殖器疣的频率。根据最新的免疫实践咨询委员会(ACIP)的建议,建议采用以下方案:(a).男性和女性在11岁或12岁时接种HPV疫苗。(b)26岁以下所有人的追赶疫苗接种。(c).关于27-45岁人群潜在HPV疫苗接种的共享临床决策,谁有新的HPV感染的风险。2.男性包皮环切术(LE:2a):相互矛盾的证据。
未经批准:在受艾滋病毒影响的个体中,HPV的病程更具侵略性,治疗抵抗的风险更大,增加上皮内瘤形成和癌症的机会。
方法:医师给药。1.光动力疗法(LE:1a)。2.激光(LE:2b)。3.手术(LE:1a)。4.电外科(LE:2c)。5.冷冻疗法(LE:1b)。6.免疫治疗(LE:1b)。7.Podphylin(LE:1b)。提供商管理。1.咪喹莫特5%(LE:1a)。2.鬼臼毒素(LE:1b)。3.Sinecatechins(LE:1a)。4.西多福韦(LE:3)。5.5-氟尿嘧啶(LE:1a)。6.干扰素(LE:1a)。
The present
guidelines aim to provide comprehensive information on genital condyloma acuminata, including the epidemiology, clinical features, diagnosis and management. The
guidelines provide evidence-based recommendations on the diagnosis, prevention and treatment of genital condyloma acuminata in adults in Asia, including patients with HIV co-infection.
METHODS: A PubMed search was performed, using the keywords \"condyloma acuminata\", \"anal wart\", \"anogenital wart\", \"genital wart\" and \"genital HPV\". A total of 3031 results were found in publications during last six years. A careful review of the titles and abstracts was done to find all the studies pertaining to epidemiology, clinical features, diagnosis, treatment and prevention of condyloma acuminata.
METHODS: Various diagnostic procedures described are: 1. PCR (LE: 2b). 2. Serology (LE: 2b). 3. In-situ hybridization (LE: 3).
CONCLUSIONS: 1. Vaccination (LE: 1a): Quadrivalent vaccine reduced the frequency of anogenital warts in both vaccinated and unvaccinated contacts. According to the update Advisory Committee on Immunization Practices (ACIP) recommendations, the following protocol is recommended: (a). HPV vaccination at age 11 or 12 years for both males and females. (b). Catch-up vaccination for all persons through age 26 years. (c). Shared clinical decision-making regarding potential HPV vaccination for persons aged 27-45 years, who are at risk of new HPV infection. 2. Male circumcision (LE: 2a): conflicting evidence.
UNASSIGNED: In HIV-affected individuals, the course of HPV is more aggressive, with a greater risk of treatment resistance, increased chances of intraepithelial neoplasia as well as cancers.
METHODS: Physician administered. 1. Photodynamic therapy (LE: 1a). 2. Laser (LE: 2b). 3. Surgery (LE: 1a). 4. Electrosurgery (LE: 2c). 5. Cryotherapy (LE: 1b). 6. Immunotherapy (LE: 1b). 7. Podophyllin (LE: 1b). Provider administered. 1. Imiquimod 5%(LE: 1a). 2. Podophyllotoxin (LE: 1b). 3. Sinecatechins (LE: 1a). 4. Cidofovir (LE: 3). 5. 5- Fluorouracil (LE: 1a). 6. Interferon (LE: 1a).